Calt Biopharm

Calt Biopharm is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative antibody therapeutics for autoimmune and inflammatory diseases. The company leverages a proprietary high-throughput screening platform to identify high-affinity monoclonal and bispecific antibodies targeting validated pathways such as IL-17 and IL-4Rα. Calt Biopharm's pipeline is designed to address significant unmet medical needs in dermatology, rheumatology, and respiratory medicine. By focusing on optimized molecular design, the company aims to provide more effective and safer treatment options for patients with chronic inflammatory conditions.